AtheroGenics Completes Enrollment Of Phase III AGI-1067 Diabetes Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim data from the randomized, double-blind, placebo-controlled trial are expected in the second quarter of 2008.